Indiana University

Scott Cooper

Hal E Broxmeyer

Li Lu

Charles Mantel

Qingchun Cai

Maegan Lynn Capitano

Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with insufficient quantity and/or quality of hematopoietic stem cells (HSCs) and differentiated blood cells thereof. Embodiments include compositions and methods for treating the condition/disease, comprising the step of providing to a subject at least one therapeutically effective dose of a composition disclosed herein. Other embodiments include methods for generating and/or collecting hematopoietic stem cells from a subject.

Compositions and methods for treating a clinical condition through the use of hematopoietic stem cells

Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).

Methods for suppressing myeloid cells with chemokines

Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.) in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).

Growing community of inventors

Indianapolis, IN, United States of America

Scott Cooper